Celiac Diseases at A Glance

Celiac disease is a serious autoimmune disorder in which the ingestion of gluten leads to damage of the small intestine, it can occur in genetically predisposed people. The global celiac disease market is expected to grow significantly due to low awareness about celiac disease among clinics as well as patient. It is predicated that celiac disease affect 1 in 100 people globally. Millions of people in developed as well as developing countries are undiagnosed and are at risk for long-term health complications. When people with celiac disease eat gluten, their immune system starts attacking the small intestine. Due to these attack, the villi that promote nutrient absorption gets damaged. When villi get damaged, the body is unable to absorb nutrients properly. Celiac disease is hereditary. This disease can develop at any age after people start eating gluten containing food or medicine. It can lead to serious health issues such as dermatitis herpetiformis, anaemia, Type I diabetes and multiple sclerosis (MS), osteoporosis, infertility and miscarriage. Further, it can also lead to serious neurological conditions such as epilepsy and migraines, short stature, and intestinal cancers, if it left untreated. Strict gluten-free diet is the only treatment for celiac disease currently. 

Celiac Disease Market

The World Gastroenterology Organization has divided celiac disease into two types, classical and non-classical. In classical celiac disease, the patients have symptoms such as steatorrhea, diarrhoea and weight loss or growth failure in children. Whereas in non-classical celiac disease, without clear signs of malabsorption, the patients may have mild gastrointestinal symptoms. The patient may suffer from abdominal distension and pain, peripheral neuropathy, unexplained chronic hypertransaminasemia, iron-deficiency anaemia, chronic fatigue, chronic migraine, reduced bone mass and bone fractures, and vitamin deficiency, late menarche/early menopause and unexplained infertility, dental enamel defects, depression and anxiety, and dermatitis herpetiformis. 

People as well as healthcare provider are not aware about celiac disease which can lead to increasing prevalence of celiac disease. According to Beyond Celiac, in 2016, in the developing world, the prevalence of celiac disease in low-risk populations is 0.14–5.7%, whereas in high risk populations is 1.2–55%. Celiac disease is a very common disorder in India, North Africa, the Middle East, and Pakistan. In sub-Saharan Africa, the incidence of celiac disease is low due to lack of awareness, low availability of diagnostic tools, and lower gluten exposure due to different diets. Further, in China, both the celiac disease is not rare in the Jiangsu and Zhejiang region. however, due to better diagnostic tools and thorough screening of individuals, there has been a significant increase in the numbers of new cases of celiac disease. 

Government are taking initiatives and introducing awareness program that will significant contribute in the global celiac disease market globally. May is considered as a celiac awareness month. Members of the celiac disease community introduce May as a celiac awareness month to raise awareness of this serious genetic autoimmune disease. The organization has created content that can be shared over internet or in clinics that will enable diagnosis of celiac disease more actively. The community invites researchers to share, support, and add their voice to drive research for treatments. The organization offer videos, infographic, images to increase the awareness among people. 

In addition to increasing awareness, research and development for the treatment of celiac disease is also increasing. Beyond Celiac performs research and development as well as drug discovery to discover the treatment of celiac disease. Many drugs are under pipeline such as IMGX-003 (ImmunogenX), KumaMax (PvP Biologics and Takeda Pharmaceuticals), Larazotide Acetate (Innovate), Name TBD (Sitari/GSK), ZED 1227 (Zedira and Dr. Falk), and TIMP-GLI (Cour Pharmaceuticals and Takeda Pharmaceuticals). Various pharmaceuticals are developing drugs for the treatment of celiac disease such as BioLineRx, Bioniz Therapeutics, Calypso Biotech, Celimmune, Cour Pharmaceuticals, ImmunogenX, ImmusanT, Innovate Biopharmaceuticals, Mayo Clinic, PvP Biologics, Selecta Biosciences, Sitari Pharma, Takeda Pharmaceuticals and Zedira. During Celiac Awareness Month, in 2018, Beyond Celiac has received $54,000 for celiac disease research from donations made by shoppers at Party City. This donation will accelerate treatments for celiac disease depends upon involvement of clinical and basic scientists for celiac disease research. A potential celiac disease vaccine is moving closer to commercialization which will contribute in the global celiac disease market in near future.

Contact:

Anurag Tiwari

Email: info@omrglobal.com

Phone: +91 7803040404, +1 6467557667

Website: www.omrglobal.com